These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32435663)

  • 1. Allopregnanolone in postpartum depression: Role in pathophysiology and treatment.
    Meltzer-Brody S; Kanes SJ
    Neurobiol Stress; 2020 May; 12():100212. PubMed ID: 32435663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [GABAergic approach of postpartum depression: A translational review of literature].
    Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
    Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexanolone, a GABA
    Edinoff AN; Odisho AS; Lewis K; Kaskas A; Hunt G; Cornett EM; Kaye AD; Kaye A; Morgan J; Barrilleaux PS; Lewis D; Viswanath O; Urits I
    Front Psychiatry; 2021; 12():699740. PubMed ID: 34594247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating brexanolone for the treatment of postpartum depression.
    Payne JL
    Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopregnanolone in Postpartum Depression.
    Pinna G; Almeida FB; Davis JM
    Front Glob Womens Health; 2022; 3():823616. PubMed ID: 35558166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroactive Steroids and GABAergic Involvement in the Neuroendocrine Dysfunction Associated With Major Depressive Disorder and Postpartum Depression.
    Maguire J
    Front Cell Neurosci; 2019; 13():83. PubMed ID: 30906252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
    Reddy DS; Mbilinyi RH; Estes E
    Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone loading as a strategy for treating postpartum depression.
    Barak Y; Glue P
    Hum Psychopharmacol; 2020 May; 35(3):e2731. PubMed ID: 32250509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
    Faden J; Citrome L
    Ther Adv Psychopharmacol; 2020; 10():2045125320968658. PubMed ID: 33224470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Brexanolone for Postpartum Depression.
    Scarff JR
    Innov Clin Neurosci; 2019 Nov; 16(11-12):32-35. PubMed ID: 32082941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexanolone: First Global Approval.
    Scott LJ
    Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barbiturates and pyrazolopyridines for the treatment of postpartum depression-repurposing of two drug classes.
    Horwitz AB; Rubin RT
    Front Pharmacol; 2023; 14():1139889. PubMed ID: 36909181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating Postpartum Depression: What Do We Know about Brexanolone?
    Ali M; Aamir A; Diwan MN; Awan HA; Ullah I; Irfan M; De Berardis D
    Diseases; 2021 Jul; 9(3):. PubMed ID: 34287271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.
    Cutler AJ; Mattingly GW; Maletic V
    Transl Psychiatry; 2023 Jun; 13(1):228. PubMed ID: 37365161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins.
    Almeida FB; Nin MS; Barros HMT
    Neurobiol Stress; 2020 May; 12():100218. PubMed ID: 32435667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.